Weight loss drugs are set to become a disproportionate share of Lilly's business.

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports ...

Eli Lilly and Novo Nordisk are expected to announce price reductions for their weight-loss drugs as part of the TrumpRx ...

Live Updates Live Coverage Has Ended Get The Best Vanguard S&P 500 ETF Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top analysis on Vanguard S&P 500 ETF, market updates, ...

Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...

Metsera stock bidding war intensifies as Novo and Pfizer race to secure next-gen obesity drug assets amid surging market ...

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

LONDON (Reuters) -Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the ...

Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the ...

Investing.com -- Eli Lilly and Novo Nordisk are planning to announce new drug pricing deals with the White House that include their weight loss medicines, according to a Tuesday report from Endpoints ...

Eli Lilly and Novo Nordisk plan to announce new drug pricing deals with the White House, including for their weight loss medicines, in return for Medicare coverage of their products, ...